Skip to main content
main-content
Erschienen in: Current Allergy and Asthma Reports 10/2022

31.08.2022 | Immune Deficiency and Dysregulation (C Kuo, Section Editor)

Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?

verfasst von: Daniel Victor Šimac, Tea Štimac, Srđan Novak

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hereditary angioedema (HAE) is a disorder affecting bradykinin regulation presenting as recurrent cutaneous or mucosal swelling. Treatment options include plasma-derived or human-recombinant C1-inhibitor, icatibant, or ecallantide. Due to the lack of knowledge and experience on the topic, the treatment of choice in pregnancy is plasma-derived C1-inhibitor, and reporting any new experience is recommended. This review presents current guidelines for HAE treatment with a focus on pregnancy and reviews all experience with icatibant use during pregnancy.

Recent Findings

Our experience of treating a pregnant nC1-INH HAE patient with icatibant is presented, with no adverse effects or abnormalities, to add to the growing knowledge of icatibant use during pregnancy.

Summary

Considering the limited number of attacks that our patient usually experiences, which continued at more or less the same frequency during pregnancy, we feel icatibant to be a safe choice for on-demand HAE treatment during pregnancy for such cases.
Literatur
2.
Zurück zum Zitat • Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. [Internet]. 2012;129(2):308–20. Available from: https://​www.​jacionline.​org/​article/​S0091-6749(11)01830-6/​fulltext. [Accessed 17 Jan 2020].  Most recent guidelines on treatment of female and pregnant HAE patients, goes into greater detail on the presentation of HAE in these patients. • Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. [Internet]. 2012;129(2):308–20. Available from: https://​www.​jacionline.​org/​article/​S0091-6749(11)01830-6/​fulltext. [Accessed 17 Jan 2020].  Most recent guidelines on treatment of female and pregnant HAE patients, goes into greater detail on the presentation of HAE in these patients.
7.
Zurück zum Zitat González-Quevedo T, Larco JI, Marcos C, Guilarte M, Baeza ML, Cimbollek S, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. [Internet]. 2016;26(3):161–7. Available from: http://​www.​jiaci.​org/​summary/​vol26-issue3-num1363. [Accessed 17 Jan 2020]. González-Quevedo T, Larco JI, Marcos C, Guilarte M, Baeza ML, Cimbollek S, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. [Internet]. 2016;26(3):161–7. Available from: http://​www.​jiaci.​org/​summary/​vol26-issue3-num1363. [Accessed 17 Jan 2020].
Metadaten
Titel
Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
verfasst von
Daniel Victor Šimac
Tea Štimac
Srđan Novak
Publikationsdatum
31.08.2022
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 10/2022
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-022-01040-3

Neu im Fachgebiet HNO

07.12.2022 | Praxis konkret

Haftungsrisiken in der Praxis reduzieren

Welche Versicherungen sich lohnen - und welche nicht

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.